体内代谢法研究糖类药物对大鼠CYP3A4的影响  

Effect of Oligo-and Poly-Saccharide on CYP3A4 Using the Metabolic Method in Vivo

作　　者：石杰[1] 耿美玉[2] 曹勇[1] 张新惠[1] 

机构地区：[1]青岛市立医院药物研究室,山东青岛266011 [2]中国海洋大学海洋药物研究所,山东青岛266003

出　　处：《中国药学杂志》2006年第22期1738-1741,共4页Chinese Pharmaceutical Journal

摘　　要：目的研究不同结构的糖类药物对肝药酶的影响,从而对这些新药进行安全性评价,并预测它们与其他药物合用的不良相互作用。方法通过研究肝药酶的专属探针药物的体内代谢过程的变化,进而判断不同结构糖类药物对这些酶有无诱导或抑制作用。结果SPMG对雌雄大鼠均有显著的抑制作用,但AOSC对CYP3A4无影响。结论结构不同的药物对CYP3A4的影响存在明显的差异,药物与各种与CYP3A4酶代谢有关的药物合用时,应充分考虑其对肝药酶的不同影响,以避免潜在的毒性或不良反应。OBJECTIVE To investigate the effects of oligo- and poly-saccharide on CYP3A4 for the safety assessment. METHODS The metabolic changes of midazolam as the probe drug was studied in vivo, then the inhibition or induction effects of oligo- and poly-saccharide with different structure were estimated. RESULTS SPMG inhibited CYP3A4 in vivo while no effect of AOSC was obtained. CONCLUSION There were obvious differences between the effects of oligo- and poly-saccharide on CYP3A4 enzymes. When oligo- and poly-saccharide are used combined with other drugs which are metablized by CYP3A4 enzyme, the different effects should be considered to avoid the potential adverse reactions.

关 键 词：糖类药物 肝药酶CYP3A4 体内 代谢法 

分 类 号：R969[医药卫生—药理学]